Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2005

View Archived Issues

Positive preclinical results for HIV protease inhibitor PPL-100

NTR1: an RVM target for antinociception

Follistatin improves pulmonary fibrosis in rats

ALGRX-4975 induces significant pain relief in patients with Morton's neuroma

Virulizin phase III study results announced

Positive in vitro results for bactericidal antibiotic AR-709

Submission for Zimycan deemed a complete response

Phase II trial begins for Elacyt in malignant melanoma

Galapagos acquires BioFocus

Companies gear up efforts for possible flu pandemic

Dosing begins in phase I study of rFXIII in cardiac surgery patients

Phase I study begins for SEP-225289 for major depressive disorder

Phase III clevidipine safety trials to resume

Financing to support continuation of phase III clinical benefit study of Riquent

Next-generation cephalosporin PPI-0903 begins phase II study

ADT trial of Acapodene reaches target enrollment

Study to investigate if comprehensive antiplatelet therapy prevents heart damage

Biopure updates status of Hemopure development program

Polypill therapy may result promising for NAFLD

ProK-60: a new antiaging product

Snapshots on new products in the treatment of MS

Preliminary phase II data on the safety of erlotinib plus bevacizumab in kidney cancer

Good safety and pharmacokinetic profile of tolvaptan in CHF patients

Recent patents cover novel treatments for psychiatric disorders

Prostanoid EP2 receptor agonists for gynecological disorders claimed in recent Pharmagene patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...